P4A is hosting a three-part webinar series on Gene Therapy

Gene Therapy is emerging as the new frontier of human medicine with the potential to cure hard-to-treat rare diseases. The human genome project’s conclusion in 2003 followed by the first gene therapy approval in Europe (2012) and the US (2017) were key milestones.

However, very little is known about this approach to treatment, creating myths and expectations.

During the P4A webinar series, we will uncover these myths – from clinical evidence to commercial concerns and put forth the readiness of key markets to adopt and integrate gene therapies.

We will gain expert insights from a cross-section of stakeholders from the medical community, patients to industry and payers.


Webinar 1: Gene-therapy a revolution or evolution of healthcare?

In the first of three webinars held in November 2017, P4A provided historical context, understanding of what gene therapy is; its clinical and environmental challenges and whether it has the potential to truly revolutionise the healthcare environment.

Key topics discussed at the webinar included:

  • What is gene therapy and its development process?
  • What are the common myths and misconceptions associated with gene therapy?
  • What are the main challenges in assessing patient eligibility?
  • From a patient’s perspective, what are the primary concerns when using or prescribed to use gene therapy?


Sophie Schmitz Managing Partner, Partners 4 Access

Sophie is a leading expert on rare diseases and orphan drugs. She is heavily involved in advising orphan drug clients on price and market access strategies, with the ultimate goal of optimizing their launch. In a 20-year career span, Sophie has worked in various pharmaceutical therapy areas and medical devices focusing on key product launches in both strategic planning & implementation.



Reina Improgo  Senior Research Scientist, Idera Pharma

Reina ImprogoReina is a biomedical scientist with more than 15 years of experience in laboratory research and scientific writing. Prior to her current role, Reina was a postdoctoral scientist at the Dana-Farber Cancer Institute, Harvard Medical School and was concurrently a visiting postdoctoral scientist at the Broad Institute of MIT and Harvard. She holds a PhD in Biomedical Sciences from University of Massachusetts Medical School.




Ermir Kalaj        Program Head, Cell and Gene Therapy, Bocconi Business School

Ermir Kalaj As Global Development Leader, Ermir leads and directs the Global cross functional   core Project Team (GPT) in gene therapy across all stages of project lifecycle. He   also leads the overall global team to develop and commercialize gene therapy   treatments in collaboration with partners from pharmaceutical industry. Prior to this, Ermir has several years experience in the pharmaceutical and particularly, in   gene therapy.



If you missed the event, you can download the webinar here.

If you missed the event, you can download the webinar here.